Ovid Therapeutics (FRA:1OT) 3-Year EBITDA Growth Rate : 16.20% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics 3-Year EBITDA Growth Rate?

Ovid Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.22.

During the past 3 years, the average EBITDA Per Share Growth Rate was 16.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ovid Therapeutics was 25.50% per year. The lowest was -47.20% per year. And the median was 16.20% per year.

Competitive Comparison of Ovid Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Ovid Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovid Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's 3-Year EBITDA Growth Rate falls into.

Ovid Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ovid Therapeutics (FRA:1OT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ovid Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovid Therapeutics (FRA:1OT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (FRA:1OT) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

OVID:USA

Address

441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website

https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics (FRA:1OT) Headlines

No Headlines